Anko Bio announced that its joint ventures, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anko Cell Technology Co., Ltd., recently received the Minutes of the Phase II Communication Meeting for PA3-17 Injection from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), approving the applicant to conduct a pivotal Phase II clinical trial of PA3-17 Injection. PA3-17 Injection is the world's first autologous CD7-targeted CAR-T cell therapy product independently developed by Boshengji Anko to receive IND approval for the treatment of relapsed or refractory CD7-positive hematolymphoid malignancies in adults.